(D-15) of nifedipine (NF), prepared by using a solid dispersion system of polyethylene glycol 4000 as a water-soluble carrier and cellulose acetate phthalate as a poorly water-soluble-carrier, were administered to healthy volunteers, and their sustained-release characteristics, bioavailability and clinical utility were investigated. It was found that D-15 was able to maintain a therapeutically effective level of NF from 30 min to 10 h without causing an excessively high peak level and offered good bioavailability.
(Received June 25, 1986) Double layer suppositories (D-15) of nifedipine (NF), prepared by using a solid dispersion system of polyethylene glycol 4000 as a water-soluble carrier and cellulose acetate phthalate as a poorly water-soluble-carrier, were administered to healthy volunteers, and their sustained-release characteristics, bioavailability and clinical utility were investigated. It was found that D-15 was able to maintain a therapeutically effective level of NF from 30 min to 10 h without causing an excessively high peak level and offered good bioavailability.
From the results of pharmacokinetic analysis by using the compartment model method, it appeared that the plasma concentrationtime course after rectal administration of D-15 is satisfactorily accounted for by a one-compartment model with first-order release and absorption steps. The value of release rate constant of D-15 obtained was smaller than that of absorption rate constant, and the sustained-release effect was apparently attributed to the slow release of NF from the suppository.
The plasma level of NF rapidly decreased as removing D-15, and the plasma level showed hardly any irregularities arising from the removal and the renewal of suppositories.
Accordingly, it was concluded that D-15 is an effective sustained-release dosage from and represents a convenient mode of therapy with reduced frequency of drug administration and reduced risk of side-effects. Keywords Nifedipine (NF), a calcium channel blocker, is increasingly used in the treatment of hypertension and angina pectoris.2) However, NF is inactivated rapidly through oxidative biotransformation, resulting in a short duration of action.3) Therefore, several sustainedrelease dosage forms of NF have recently been developed in an attempt to reduce the frequency of drug administration and the incidence and intensity of side-effects.4,5) A few studies on rectal sustained-release dosage forms of NF have been carried out 6,7 Kleinbloesem et al.8) reported that NF could be given rectally through an osmotic pump system at zero-order rate for 24 h.
In the previous paper,7) we reported that double layer suppositories of NF prepared by using a solid dispersion system of polyethylene glycol 4000 (PEG) as a water-soluble carrier and cellulose acetate phthalate (CAP) as a poorly water-soluble carrier show a sustainedrelease effect and good bioavailability in rabbits.
In this paper, the double layer suppositories of NF reported previously7) were administered to healthy volunteers, and their bioavailability and clinical utility were investigated. 
Results and Discussion
Plasma Levels of NF after Rectal Administration Figure 1 shows the plasma concentration-time curves of NF after rectal administration of C-0 and D-15. The absorption of NF after administration of C-0 was very fast, and the mean maximum plasma concentration was 80.1 ng/ml at 1 h. Subsequently, the plasma level declined rapidly to a value below 10 ng/ml at 8 h after administration (Fig. 1) . On the other hand, the administration of D-15 resulted in a plateau plasma level in the range of 20-35 ng/ml from 30 min to 10 h (Fig. 1) .
Aoki et al.10) reported that the lowest therapeutically effective level of NF may be in the range from 20 to 30 ng/ml, and Stern et al.11 ) reported that the minimum toxic concentration of NF is not necessarily constant, but adverse effects such as headache and flushing may be to Healthy Volunteers observed at plasma concentrations exceeding 50-70 ng/ml. In our experiments, all volunteers experienced side-effects such as headache, flushing or dizziness after administration of C-0, in particular at the time of peak plasma level. However, no marked side-effects were observed during administration of D-15. From these results, it was concluded that D-15 is a suitable dosage form for obtaining a desirable level of NF for a long time.
Pharmacokinetic Analysis
The plasma concentration-time course of NF after intravenous administration to rabbits or man follows a two-compartment model.3,12-13) On the other hand, it is known that the plasma concentration-time course after oral administration is consistent with a onecompartment model with a first-order absorption step because of the fusion of compartments, even though the plasma concentration-time course after intravenous administration is explained by a two-compartment model.14)
Therefore, the pharmacokinetic analysis of the plasma concentration-time course of NF after rectal administration of C-0 was performed according to a one-compartment model with a first-order absorption step, as shown in Fig. 2 (model A) . The calculated plasma concentration-time curve fitted well with the observed plasma data, as can be seen in Fig. 1 . These results suggest that the plasma concentration-time course after rectal administration of C-0 follows a one-compartment model with a first-order absorption step.
Furthermore, the curve fitting of the plasma concentration-time course data after rectal administration of D-15 was carried out by using a one-compartment model with two consecutive first-order steps in order to clarify the release rate of NF from a suppository, as shown in Fig. 2 (model B) . The computer analysis was done by simultaneous fitting of the equation for both C-0 and D-15. The calculated plasma concentration-time curve was successfully fitted to the observed plasma data (Fig. 1) . From these results, it appears that the plasma concentration-time course after rectal administration of D-15 is satisfactorily accounted for by a one-compartment model with first-order release and absorption steps. The pharmacokinetic parameters obtained are listed in Table I .
The value of absorption rate constant (ka) or elimination rate constant (K) was not significantly different between C-0 and D-15, and the value of release rate constant (k r) was smaller than that of ka. From these results, it was concluded that the sustained-release effect achieved by D-15 is apparently attributable to the slow release of NF from a suppository. On the other hand, the areas under the plasma concentration-time curves (AUC) of C-0 and D-15 were almost the same.
Removal and Renewal of D-15
One serious disadvantage of oral sustained-release preparations is the lack of flexibility on administration.15 In the case of an oral sustained-release dosage form, it is difficult to respond to changes in the condition of a patient, because its action is maintained for 8 12 h once it is administered. Figure 3 shows the effect of removal of D-15 at 2 h after administration on the plasma concentration-time course. When the suppository was removed, the plasma level of NF rapidly decreased. These results suggest that D-15 is much safer than oral sustained-release preparations.
The effect of renewal of D-15 on the plasma concentration-time course is shown in Fig.  4; i.e., D-15 was removed at 2 h after administration and then a new D-15 was inserted after 
